Camurus AB England United Kingdom Sweden

and LinkedIn.

References

Oczyesa® SmPC.Colao A., et al. Acromegaly. Nat Rev Dis Primers. 2019;5(1):20.Webb SM, et al. Quality of Life in Acromegaly. Neuroendocrinology. 2016;103(1):106-111.Fleseriu M., et al Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022 Nov;10(11):804-826. Crisafulli S., et al. Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinology. 2021; 185:251-63. Summary of Product Characteristics, Sandostatin LAR 20 mg: https://assets.hpra.ie/products/Human/22656/Licence_PA0896-028-005_03012024152159.pdfFerone, D., et al. J Clin Endocrinol Metab. Published 8 October, 2024. Press release 15 July, 2024: https://www.camurus.com/media/press-releases/2024/camurus-announces-positive-phase-3-results-from-the-acroinnova-2-study-of-octreotide-sc-depot-cam2029-in-acromegaly-patients/ 

This information was submitted for publication at 4.45 pm CET on 28 August 2025.

CONTACT:

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/camurus-ab/r/camurus-announces-approval-of-oczyesa--for-the-treatment-of-acromegaly-in-the-uk,c4226147

The following files are available for download:

https://mb.cision.com/Main/13456/4226147/3635322.pdf

Press release

View original content:https://www.prnewswire.co.uk/news-releases/camurus-announces-approval-of-oczyesa-for-the-treatment-of-acromegaly-in-the-uk-302541276.html